{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:31:09Z","timestamp":1790487069820,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2015,2,13]],"date-time":"2015-02-13T00:00:00Z","timestamp":1423785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,2,13]],"date-time":"2015-02-13T00:00:00Z","timestamp":1423785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1038\/leu.2015.35","type":"journal-article","created":{"date-parts":[[2015,2,13]],"date-time":"2015-02-13T07:37:26Z","timestamp":1423813046000},"page":"1792-1794","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells"],"prefix":"10.1038","volume":"29","author":[{"given":"L","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V A","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T M","family":"Leclercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T P","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D L","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,13]]},"reference":[{"key":"BFleu201535_CR1","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","volume":"104","author":"J Thomas","year":"2004","unstructured":"Thomas J, Wang L, Clark RE, Pirmohamed M . Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004; 104: 3739\u20133745.","journal-title":"Blood"},{"key":"BFleu201535_CR2","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","volume":"110","author":"DL White","year":"2007","unstructured":"White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007; 110: 4064\u20134072.","journal-title":"Blood"},{"key":"BFleu201535_CR3","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","volume":"108","author":"DL White","year":"2006","unstructured":"White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006; 108: 697\u2013704.","journal-title":"Blood"},{"key":"BFleu201535_CR4","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1182\/blood-2004-04-1398","volume":"104","author":"H Burger","year":"2004","unstructured":"Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2 drug pump. Blood 2004; 104: 2940\u20132942.","journal-title":"Blood"},{"key":"BFleu201535_CR5","doi-asserted-by":"publisher","first-page":"747","DOI":"10.4161\/cbt.4.7.1826","volume":"4","author":"H Burger","year":"2005","unstructured":"Burger H, van Tol H, Brok M, Wiemer EA, de Bruijn EA, Guetens G et al. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther 2005; 4: 747\u2013752.","journal-title":"Cancer Biol Ther"},{"key":"BFleu201535_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/sj.leu.2403257","volume":"18","author":"T Illmer","year":"2004","unstructured":"Illmer T, Schaich M, Platzbecker U, Freiberg-Richter J, Oelschlagel U, von Bonin M et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004; 18: 401\u2013408.","journal-title":"Leukemia"},{"key":"BFleu201535_CR7","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","volume":"101","author":"FX Mahon","year":"2003","unstructured":"Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003; 101: 2368\u20132373.","journal-title":"Blood"},{"key":"BFleu201535_CR8","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1124\/mol.65.6.1485","volume":"65","author":"C Ozvegy-Laczka","year":"2004","unstructured":"Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 2004; 65: 1485\u20131495.","journal-title":"Mol Pharmacol"},{"key":"BFleu201535_CR9","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3324\/haematol.2011.056457","volume":"97","author":"DL White","year":"2012","unstructured":"White DL, Radich J, Soverini S, Saunders VA, Frede AK, Dang P et al. Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. Haematologica 2012; 97: 907\u2013914.","journal-title":"Haematologica"},{"key":"BFleu201535_CR10","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1158\/1535-7163.MCT-12-0302","volume":"11","author":"R Sen","year":"2012","unstructured":"Sen R, Natarajan K, Bhullar J, Shukla S, Fang HB, Cai L et al. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. Mol Cancer Ther 2012; 11: 2033\u20132044.","journal-title":"Mol Cancer Ther"},{"key":"BFleu201535_CR11","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-07-5095","volume":"14","author":"DK Hiwase","year":"2008","unstructured":"Hiwase DK, Saunders V, Hewett D, Frede A, Zrim S, Dang P et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 2008; 14: 3881\u20133888.","journal-title":"Clin Cancer Res"},{"key":"BFleu201535_CR12","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00210-001-0489-7","volume":"364","author":"C Pauli-Magnus","year":"2001","unstructured":"Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF . Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 2001; 364: 551\u2013557.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"BFleu201535_CR13","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.3109\/10428194.2011.591013","volume":"52","author":"C Tang","year":"2011","unstructured":"Tang C, Schafranek L, Watkins DB, Parker WT, Moore S, Prime JA et al. Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways. Leuk Lymphoma 2011; 52: 2139\u20132147.","journal-title":"Leuk Lymphoma"},{"key":"BFleu201535_CR14","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1182\/blood-2005-03-1103","volume":"106","author":"D White","year":"2005","unstructured":"White D, Saunders V, Lyons AB, Branford S, Grigg A, To LB et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 2005; 106: 2520\u20132526.","journal-title":"Blood"},{"key":"BFleu201535_CR15","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1038\/bjc.2012.173","volume":"106","author":"J Wang","year":"2012","unstructured":"Wang J, Hughes TP, Kok CH, Saunders VA, Frede A, Groot-Obbink K et al. Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells. Br J Cancer 2012; 106: 1772\u20131778.","journal-title":"Br J Cancer"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201535.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201535","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201535.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:23:17Z","timestamp":1648743797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,13]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["BFleu201535"],"URL":"https:\/\/doi.org\/10.1038\/leu.2015.35","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,13]]},"assertion":[{"value":"13 February 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TPH is an Advisory Board member and has received research funding and honoraria from Novartis and Bristol-Myers Squibb (Membership on an entity\u2019s Board of Directors or advisory committee). DLW has received research funding and honoraria from Novartis and Bristol-Myers Squibb. Although Ariad provided drug for these laboratory-based studies, they had no role in the analysis of the data or the preparation of the manuscript. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}